Bruce Hamilton

Bruce Hamilton

Company: Labcorp Oncology

Job title: Director of Biopharmaceutical Development

Bio:

Bruce J. Hamilton, PhD, MSc

Drug Development Team Leader

Early Phase Development Solutions

Huntingdon, Cambridgeshire, UK

Key Roles and Responsibilities

  • Manages team of Drug Development Leaders specializing in the development of Biological (mAb, cell, gene) therapies, oligonucleotides and vaccines
  • Assists in the strategic planning and execution of clients’ drug development programs
  • Consults with clients to solve organizational, technical, scientific and/or regulatory challenges
  • Member of a cross enterprise team focused on Cell and Gene Therapy development and Cell and Gene Therapy clients

Areas of Expertise

  • Monoclonal Antibody/Bispecific/Antibody Fragment Development
    • Selection, characterization, formulation, preclinical Proof of Concept, pharmacokinetics (PK)/pharmacodynamics (PD), scale up and manufacture, toxicology, early clinical development
  • Immuno-oncology Checkpoint Inhibitors Preclinical Development
    • In vitro human testing, Proof of Concept (syngeneic testing), toxicology
  • Drug conjugates, ADCs and peptides
    • Selection, characterization, Proof of Concept (xenograft models), PK/PD, scale up, toxicology, early clinical development
  • Type II Diabetes/Obesity Peptide Hormone Medicines
    • Design, Proof of Concept, PK/PD, scale up, toxicology
  • Cell and Gene Therapy
    • Development strategies, toxicity, biodistribution testing
  • Broader Commercial Strategies for Start-ups
    • Intellectual property, competitor analysis, reimbursement

Professional Highlights

  • More than 20 years of pharmaceutical research and development experience
  • Experience with large pharma and biotech drug development paradigms, multiple licensing and co-development deals
  • Has been responsible for end-to-end delivery (from compound selection to completion of IND enabling studies/initiation of clinical testing) of three compounds
  • Managed portfolios of development projects at various stages, managing risk and timelines to accelerate drug development, prioritize resources and maximize commercial value
  • Participated in one Biotech sale to large Pharma (Domatis to GSK) and securing Series A funding subsequently enabling NASDAQ listing (Bicycle Therapeutics)
  • Before joining Covance, was Director, New Product Development, Abcam
  • Also held previous positions with Medimmune, Bicycle Therapeutics, GlaxoSmithKline, and Astex Therapeutics
  • Holder of more than a half-dozen patents
  • Author or co-author of peer-reviewed journal articles, book chapters, and presentations, and frequent presenter at industry conferences

Education

  • PhD, Pharmacy

Manchester University

  • MSc, Biochemistry

Oxford University

 

Publications/Journals

  • Handbook of Therapeutic Antibodies, 2nd Edition
  • Biotechnology Journal

Seminars:

Q&A 11:00 am

You can take part in this interactive Q&A by submitting questions via the live chat tabRead more

day: Agenda: Risks, Dead-ends & Avoidable Delays: Optimising Preclinical Planning & Biomarker Targets to Maximise Clinical Development in Precision & Immuno-Oncology

With the End in Mind – The Importance of an Integrated Preclinical & Clinical Approach 10:20 am

• The importance of clearly defined CDP in informing preclinical planning and execution in the Immuno-Oncology space • Learn how to optimise Go / No-Go for Immuno-Oncology agents in the preclinical space • Key lessons learned in de-risking through “end-in-mind” approach into the clinical spaceRead more

day: Agenda: Risks, Dead-ends & Avoidable Delays: Optimising Preclinical Planning & Biomarker Targets to Maximise Clinical Development in Precision & Immuno-Oncology

Q&A 11:10 am

You can take part in this interactive Q&A by submitting questions via the live chat tabRead more

day: Labcorp Oncology Engager - Agenda

With the End in Mind – The Importance of an Integrated Preclinical & Clinical Approach 10:10 am

• The importance of clearly defined CDP in informing preclinical planning and execution in the Immuno-Oncology space • Key lessons learned in de-risking through “end-in-mind” approach into the clinical spaceRead more

day: Labcorp Oncology Engager - Agenda

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.